[go: up one dir, main page]

AU1466001A - Methods of determining individual hypersensitivity to an agent - Google Patents

Methods of determining individual hypersensitivity to an agent

Info

Publication number
AU1466001A
AU1466001A AU14660/01A AU1466001A AU1466001A AU 1466001 A AU1466001 A AU 1466001A AU 14660/01 A AU14660/01 A AU 14660/01A AU 1466001 A AU1466001 A AU 1466001A AU 1466001 A AU1466001 A AU 1466001A
Authority
AU
Australia
Prior art keywords
agent
methods
determining individual
hypersensitivity
individual hypersensitivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14660/01A
Inventor
Spencer Farr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHASE-1 MOLECULAR TOXICOLOGY
Original Assignee
PHASE 1 MOLECULAR TOXICOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHASE 1 MOLECULAR TOXICOLOGY filed Critical PHASE 1 MOLECULAR TOXICOLOGY
Publication of AU1466001A publication Critical patent/AU1466001A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU14660/01A 1999-11-05 2000-11-03 Methods of determining individual hypersensitivity to an agent Abandoned AU1466001A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16539899P 1999-11-05 1999-11-05
US60165398 1999-11-05
US19657100P 2000-04-11 2000-04-11
US60196571 2000-04-11
PCT/US2000/030474 WO2001032928A2 (en) 1999-11-05 2000-11-03 Methods of determining individual hypersensitivity to an agent

Publications (1)

Publication Number Publication Date
AU1466001A true AU1466001A (en) 2001-05-14

Family

ID=26861357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14660/01A Abandoned AU1466001A (en) 1999-11-05 2000-11-03 Methods of determining individual hypersensitivity to an agent

Country Status (2)

Country Link
AU (1) AU1466001A (en)
WO (1) WO2001032928A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974831A (en) * 2019-10-21 2020-04-10 四川省人民医院 Drug combination for improving fluorouracil sensitivity and application of drug combination
CN110974829A (en) * 2019-10-21 2020-04-10 四川省肿瘤医院 Application of hydroxychloroquine linolenic acid ester in improving sensitivity of 5-Fu and evaluation method

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369969A1 (en) * 1999-04-15 2000-10-26 Curagen Corporation Method of identifying toxic agents using differential gene expression
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
AU7133000A (en) * 1999-07-02 2001-01-22 Curagen Corporation Method of identifying toxic agents using differential gene expression
EP1409718A2 (en) 2000-07-21 2004-04-21 Phase-1 Molecular Toxicology Canine toxicity genes
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
US7415358B2 (en) 2001-05-22 2008-08-19 Ocimum Biosolutions, Inc. Molecular toxicology modeling
EP1456650B1 (en) * 2001-06-05 2010-10-06 Exelixis, Inc. Gfats as modifiers of the p53 pathway and methods of use
EP1411120B1 (en) * 2001-07-05 2010-01-13 Taiho Pharmaceutical Company Limited Dna arrays for measuring sensitivity to anticancer agent
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
EP1412537A4 (en) * 2001-07-10 2005-07-27 Gene Logic Inc Cardiotoxin molecular toxicology modeling
AU2002323286A1 (en) * 2001-08-16 2003-03-03 Phase-1 Molecular Toxicology, Inc. Human toxicologically relevant genes and arrays
CN102402650A (en) 2001-11-09 2012-04-04 生命技术公司 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US20090226374A1 (en) * 2003-10-27 2009-09-10 Health Aide, Inc. Anaphylatoxins for detecting clinical conditions
GB0419481D0 (en) * 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
JP2011125218A (en) * 2008-04-11 2011-06-30 Signpost Corp Method for anticipating sensitivity to phenylalanine derivative-based compound in diabetes patient
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN105358531B (en) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 Mitochondrial aldehyde dehydrogenase-2 modulators and its application method
JP5719985B2 (en) * 2013-08-01 2015-05-20 株式会社ポーラファルマ Diphenylmethyl piperazine derivatives
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN103525926B (en) * 2013-10-08 2016-03-23 浙江大学 A kind of screening method of the drug toxicity private medical service gene marker based on gene expression profile
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (en) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459037A (en) * 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US6197551B1 (en) * 1998-01-27 2001-03-06 Millennium Pharmaceuticals, Inc. Spoil-1 protein and nucleic acid molecules and uses therefor
WO1999023254A1 (en) * 1997-10-31 1999-05-14 Affymetrix, Inc. Expression profiles in adult and fetal organs

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974831A (en) * 2019-10-21 2020-04-10 四川省人民医院 Drug combination for improving fluorouracil sensitivity and application of drug combination
CN110974829A (en) * 2019-10-21 2020-04-10 四川省肿瘤医院 Application of hydroxychloroquine linolenic acid ester in improving sensitivity of 5-Fu and evaluation method

Also Published As

Publication number Publication date
WO2001032928A9 (en) 2002-05-16
WO2001032928A3 (en) 2002-07-25
WO2001032928A2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AU1466001A (en) Methods of determining individual hypersensitivity to an agent
AU3867400A (en) Methods of using bioelastomers
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AUPQ419099A0 (en) Novel compositions and methods
AU7719100A (en) Compositions of tocol-soluble therapeutics
HK1048247A1 (en) Stable carotene-xanthophyll beadlet compositions and methods of use
AU7389300A (en) Methods of administration of glycopyrrolate compositions
AU7620200A (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU3671099A (en) Methods and compositions pertaining to pd-loops
AU3885301A (en) Anti-mycobacterium compositions and methods of preparing and using same
AU7358800A (en) Compositions and methods for modification of skin lipid content
WO2001041823A8 (en) Radioactive compositions and methods of use thereof
AU1957797A (en) Zwitterionic compositions and methods as biological response modifiers
AU2003240668A1 (en) Attenuation of metapneumovirus
AU2203801A (en) Formulations of adenosine a1 agonists
AU2003302372A1 (en) Formulations of finasteride
AU2203601A (en) Formulations of adenosine a1 agonists
AU1718301A (en) Use of sugar compositions
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
AU5476599A (en) Encapsulation of caffeine
AU4167200A (en) Reduction of latex associated hypersensitivity
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AUPO888497A0 (en) Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU1601801A (en) Methods of preparing crna

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase